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Insulin resistance and type II diabetes is a disease

state characterized by a lack of sensitivity of insulin
to provoke a proper response in insulin sensitive

tissues.

Currently, we utilize glucosamine to increase

flux through the Hexosamine Biosynthetic Pathway (HBP) to
induce an insulin resistance like state in primary rat

hepatocytes.
mimetic

We tested the effectiveness of the insulin

sodium orthovanadate

to determine

if

it could

elicit an insulin-like response under these conditions.
Mixed results were obtained on the effectiveness of

vanadate as an insulin mimetic
model.

in this

insulin resistant
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CHAPTER

I

INTRODUCTION

The word "diabetes" is latin but ultimately derived
from an ancient greek word meaning "to pass through" or
"siphon." Mellitus is also derived from a latin word mel

or mellite meaning "honey" or "to sweeten with honey, "
respectively.

The term mellitus was first used by

William Cullen in 1769 to distinguish between diabetes

mellitus and diabetes insipidus [polyuria/excessive
urination]

(Sanders 2002).
Prevalence

Insulin resistance,

of Diabetes

a hallmark of diabetes,

is a

disease state that affects millions of people worldwide.
The World Health Organization has declared that a
"diabetes epidemic is underway." Approximately 438

million people worldwide will be affected by insulin
resistance by the year 2030
time,

the U.S.

[WHO]

(Smyth 2006).

In this

is predicted to have the fourth largest

rise in new cases of diabetes

(Figure 1). Only China,

India and the Middle East are predicted to have a greater

increase in new cases by population size.

It is thought

that this new trend is due to unhealthy lifestyles (lack
of exercise), poor diets,
growth (Smyth 2006).
million Americans

aging and of course population

Right now in the United States,

have

the metabolic disease

25

state of

diabetes and another 79 million have pre-diabetic
symptoms. According to the Centers for Disease Control
and Prevention

(CDC),

if this trend continues,

Americans will have diabetes by 2050.
of health

care

associated with

estimated to be about

The growing cost

diabetes

174 billion

1 out of 3

care

in

(total cost)

2007

was

in the

United States and this figure represents a significant
amount of the overall costs that are spent on health care

every year.

Much of these costs are associated with the

direct care and treatment of the disease.

indirect costs

loss,

(58 billion)

However,

such as disability,

many

work

and premature death drive up the total cost of

treatment according to the CDC.

This figure represents a

growing epidemic that will require new and novel methods
of

control

or

treatment

to

combat

the

disease

state.
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Figure 1- Global Projections for Diabetes Epidemic
(Permission to reuse figure obtained from IDF)
http://www.idf.org/diabetesatlas/be/foreword

Type I Diabetes Mellitus

Diabetes can be attributed to many things which
include hereditary or genetic,
or even viral causes.
(IDDM)

lifestyle,

The first type,

environmental

type I diabetes

or Insulin Dependent Diabetes Mellitus is often

linked to an inherited defect.

Type I diabetes is an

autoimmune response which destroys the insulin producing
(3-cells within the pancreas.

There are two major hormones
3

produced in the pancreas and they regulate the metabolism
and flux of glucose within the body.

The hormones that

regulate this highly organized process of glucose
homeostasis are two small polypeptides,

glucagon and

insulin and they are produced by two different cell types

within the pancreas , the a and p-cells,

respectively.

Both of these cell types are located in specific regions

of the pancreas called the islets of Langerhans (Figure
2) .

isietof
Delta cei

Alpha eel •

Beta ceil

Red blood cefc

Figure 2- Cross-section of Pancreas (Bardeesy 2002).
Copyright permission obtained from Nature Publishing
Group provided by Copyright Clearance Center. (License #
2911401421218)

With the case of IDDM,

the pancreatic (3-cells are

damaged by an immune response against oneself due to a

response of the major histocompatibility complex (MHC).
This MHC is a region of the genome that is present in all
invertebrates and is responsible for production of cells
associated with an immune response.
combinations

within

the

MHC

that

are

Inherited genetic
defective

have

been

shown to produce phenotypes with autoimmune disorders. A

specific type of MHC class II molecule is presented with
a specific antigen that activates T cells through binding
of this specific antigen

that CD4-,

(Ridgway 1998) .

It was shown

CD8+ cytotoxic T cells have been found in the

islets of patients with the on-set of the disease
1986).

(Foulis

CD8+ cytotoxic T cells or killer T cells are

leukocytes or white blood cells that express a specific

glycoprotein called CD8.

This affinity for CD8 and the

MHC helps the cytotoxic T cell to recognize and target
the cells for destruction.

Also,

autoantibodies or

antibodies directed against the body's own healthy cells

which specifically target the islets of Langerhans are to
blame and believed to be the cause of the (3-cell

destruction. There are even a few laboratories emerging
with evidence that Coxsackie B viruses

(CVBs)

can induce

the type I form of diabetes although these theories are
not very popular

(Fairweather 2002).

Since insulin is no longer produced in the pancreas
it must be supplemented and individuals are treated with
multiple daily injections of insulin via needle or

insulin pump.

This treatment regiment can be difficult

for patients to control blood glucose levels not to
mention the physical burden associated with insulin

injections.

However advances have been made in the

synthetic forms of insulin produced now and these have a

longer lasting effect,

which help patients control the

blood glucose in a much narrower range with fewer
injections.
Type II Diabetes Mellitus and Insulin Resistance

Non-Insulin Dependent Diabetes Mellitus

(NIDDM)

or

Type II diabetes is a disease state whereby insulin is
produced but nonetheless ineffective in stimulating

glucose uptake and utilization.
diabetes

was

referred to

as

adult

Often times this type of
onset

diabetes.

The

complications associated with Type II diabetes has been

linked to obesity due to lack of physical exercise.
wealthier nations such as North America,

and the Middle East,

In

Great Britain

the lifestyle has been heading

toward more sedimentary one.

It is thought that

inactivity along with a vast nutrient supply can cause
overproduction of insulin,

thereby leading to

insensitivity. Cells that recognize and respond to
insulin and its signal will become insensitive as well.
When that lack of response or insulin resistance takes

place the disease state can be characterized as NIDDM.
It also seems that the (3-cells responsible for the

production of insulin eventually become overwhelmed and
exhaust their production of functional insulin.
individuals are initially diagnosed with NIDDM,
of treatment can involve exercise,

When
courses

change of lifestyle,

learning how to control blood glucose with insulin
injections as well as oral medications.
Discovery of Insulin
Diabetes is a disease that has been pondered by many

cultures since the beginning of recorded history.
7

Before

the discovery of insulin,

a diagnosis of diabetes

mellitus was a death sentence.

So for nearly three

millennia, patients with onset of the disease died early
in life and often quickly and painfully.

The research in

this area became quite vigorous and has expanded
exponentially in the last 100 years.

Prior to that,

scientists had difficulty describing diabetes let alone
treating the disease.

In 1893 two scientists,

Minkowski and Josef von Mering,

Oskar

discovered that

depancreatized dogs had lost the ability of digestion and
ability to control blood glucose

(Mering 1889).

This was

a significant finding that first proposed something
within the pancreas controlled blood glucose.

In the next

twenty years numerous scientists such as Nicolae Paulescu
(Paulescu 1921),

Kliener

George Zuelzer

(Zuelzer 1908)

and Isreal

(Kliener 1919)came up with rudimentary extracts

in an attempt to produce the mystery compound that could

have a glucose lowering effect.

The discovery of insulin

is generally agreed upon to have happened in Toronto in
1922.

Fredrick Banting and Charles Herbert Best,

under the expert tutelage of Dr.

James Macleod,

working

used an

experimental technique of duct ligation in the pancreas
of dogs that was based on a paper from Moses Barron
(Barron 1920).

This series of experiments resulted in

the isolation of extracts that were highly inconsistent
between batches and as well as their ability to lower
blood glucose.

Frustrated with these problems the group

sought the help of Dr.

James Bertram Collip.

It became a

race between Banting/Best and Collip to purify the
extract.

Collip was a biochemist that eventually

perfected the isolation and purification of insulin from
the crude extract using the right concentration of

ethanol to precipitate the peptide.

Banting and Best

wound up using beef pancreas from slaughter houses in the
area to produce an extract.

The crude extract isolated

from the pancreas was named "isletin"(Banting 1922).

On

January 11, 1922 they injected Leonard Thompson with this
extract and it failed miserably

(Banting 1922).

On

January 23, 1922 the team resumed the injection on that
same patient using the extract produced by Collip
(Banting 1922). This time the patient flourished and was

quite literally brought back from near death. This was

later produced and sold all over the world by the

Indianapolis based pharmaceutical company, Eli Lily.
Since then,

the advances in the production and synthesis

of insulin have made leaps and bounds.

In 1936,

Hans

Christian Hagedorn discovered that the effects and
duration of

insulin action could be

use of protamine.

controlled with the

These "slow-release" insulin compounds

were able to control insulin action for a period of 24-36
hours.

Later in the late 1950s,

oral medications with

anti-diabetic effects were developed that could treat
NIDDM (Jerslid 1956)

(Spencer 1956).

From 1963-1966,

insulin was chemically synthesized by several groups in
Germany (Meienhofer 1963),
United States

China

(Katsoyannis 1966).

10

(Kung 1966) , and the

Synthesis of Insulin

Insulin is synthesized in the islets of Langerhans
within the pancreas as a single polypeptide precursor
known as preproinsulin (Figure 3). This precursor
contains three distinct domains
sequence at the amino termini.
store

insulin in this

(A,B,C)

and a signal

Since the body does not

form it must

be

converted to

proinsulin by the action of a specific protease that
removes the signal sequence.

Proteolytic cleavage of the

amino terminus is immediately followed by three distinct
disulfide bond formations.

This molecule,

proinsulin,

can now be stored in the pancreatic beta cells of the

pancreas.

Proinsulin is converted to mature insulin in

response to elevated blood glucose levels.

This happens

when the C domain is removed and another specific

protease cleaves two of the three disulfide bonds. Now
insulin can be defined as two polypeptides
chain)

linked by a disulfide bond

11

(A and B

(Cox 2005).

s—s

C-Chain

C-Chain

Signal peptide

Preproinsulin

Proinsulin

Insulin

Figure 3- Conversion of Preproinsulin to Insulin.
created

in

Microsoft

Figure

PowerPoint.

Actions

of

Insulin

The actions of insulin are very broad and specific

(Figure 4).

Insulin has the distinct ability to promote

glucose uptake in muscle and fat,

promote glycolysis and

glycogen synthesis as well as protein synthesis.

Insulin

also has the ability to inhibit many other cell functions

like de novo synthesis of glucose via gluconeogensis,

lipolysis and glycogenolysis.

12

The Actions of Insulin
Gluconeogenesis

Glycogen Synthesis

Proteolysis

* Glucose Transport

Lipolysis

Glycolysis

Protein Synthesis

Glycogenosis

Figure 4- The Actions of Insulin.
Microsoft

Figure created in

PowerPoint.

Insulin is important for glucose metabolism and is
secreted by the pancreas in response to an influx of

glucose and elicits its response through binding to a
cell surface receptor.

The inherent nature of this

hormone to stimulate insulin sensitive metabolic enzymes

gives rise to numerous actions ranging from regulation of
gene expression and eventual translation to glucose

transport. An example of this would be insulin's ability
to promote the inhibition of gluconeogenesis or the

13

production of new sugars and the increased production of
lipids via lipogenesis.

Gluconeogenesis inhibition

becomes problematic when the insulin signaling cascade
fails to suppress the new production of sugar within the
liver.

When glucose concentrations in the blood are

already high and new glucose production is not inhibited
detrimental effects can be measured.

This persistent

state of elevated glucose levels is defined as diabetes.
Insulin Signaling Phosphorylation Cascade

Insulin binds to its cell surface receptor (Figure
5) initiating an insulin sensitive phosphorylation
cascade that results in activation/deactivation of

metabolic proteins or enzymes.

The insulin receptor (IR/

is comprised of two a(3 monomers which have distinct

regions and binding domains. The two alpha chains are on
the outside of the plasma membrane. They are responsible

for the binding of insulin.

The two beta chains contain

a region bound by the inner leaflet of the plasma
membrane and a portion that protrudes out into the

cytosol. This region contains a catalytic domain that
transfers a phosphoryl group from ATP to multiple
14

different substrates containing a Tyr residue such as the
insulin receptor substrate

[IRS]

IRS-4,

Upon binding of insulin to the

Cbl,

Gabl,

Gab2).

(IRS-1,

IR an auto-phosphorylation event occurs.

IRS-2,

IRS-3,

This self

phosphorylation occurs due to a conformational change in

the alpha chains when insulin binds and corresponds with
the activation of the tyrosine kinase activity of the
beta chains.

This conformational change exposes these Tyr

residues to phosphorylation and thus activation of the
IR. The IR is phosphorylated on three distinct tyrosine
residues critical to its function.

The insulin receptor

then recruits the insulin receptor substrate one

(IRS-1)

to the protein complex. All IRS proteins contain two

distinct regions at the amino terminus that allow binding
to specific proteins and regions within the cell.

The

first binding specific region is the protein tyrosine
binding (PTB) domain,

which subsequently binds to the

phospho-tyrosine residues in the IR.

The second region

is called a pleckstrin homology (PH) domain that is
specific for the binding of certain lipids at the

cytosolic side of the membrane (Parker 2001).
15

Upon IRS-1

binding to the IR domain, Phosphotidylinositol 3 Kinase

(PI3K) is recruited to the plasma membrane (Figure 5).
This now becomes known as the point of nucleation for the
protein complex.

PI3K has two distinct domains, one for

binding and one for catalytic activity.

The p85 subunit

contains a SH2 and SH3 domain which preferentially binds
phospho-tyrosine residues.

The pllO subunit is the

domain responsible for the conversion of

phosphatidylinositol 4,5-bisphosphate (PIP2)to

phosphatidylinositol 3,4,5-trisphosphate (PIP3).

Glycogen Synthesis
Protein Synthesis

Transcription

Figure 5- Insulin Signaling Cascade. Figure created in
Microsoft

PowerPoint.
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Once PIP2 is converted to PIP3, a signal is

recognized by Protein Kinase B (PKB) or Akt. Akt/PKB is a
protein kinase that belongs to a subfamily of proteins
called AGC protein kinases

[CAMP-dependent protein kinase

(PKA)/protein kinase G/protein kinase C (PKC)

(Fayard

2005) ] . Akt/PKB has three distinct regions that encompass

its binding and catalytic and/or regulatory domain.

This

protein contains a binding domain similar to that of IRS1. This N-terminal binding domain contains a PH domain

that specifically binds phospholipids at the plasma
membrane.

The

other domain

hydrophobic motif (HM)

at

the

C-terminus

contains

a

(FxxF(S/T)Y), which happens to be

the site of phosphorylation of a serine/threonine residue
(Furtado 2002).

Akt is then recruited to the plasma

membrane by PI3K indirectly due to the conversion of PIP2

to PIP3.

Upon arrival of Akt/PKB to the point of

nucleation,

it undergoes a phosphorylation by PDK-1 or

phosphoinositide-dependent kinase 1. This phosphorylation
occurs on a distinct residue Thr308.

Ser473,

A

second residue,

is thought to be phosphorylated by an

unidentified kinase or possibly auto-phosphorylation by
17

Akt itself whereby causing a conformational change
altering or increasing Akt activity 1000 fold within the
cell. Akt is also involved in apoptosis or cell survival,
cell motility and cell cycle progression.
Akt has been shown to activate pathways involving
the mechanistic target of rapamycin

(mTOR)

and a large

multi-protein complex. mTOR is activated by growth
factors such as insulin or insulin like growth factor
(IGF)

as well as a nutrient sensing pathway involving the

tuberous sclerosis complex (TSC1-TCS2)
Rag GTPases.

and the Rheb and

mTOR is involved in two multi-protein

complexes called mTORCl and mTORC2.
Akt also functions on numerous substrates that regulate

glycogen synthesis and storage to glucose transport.

Akt

can phosphorylate a target protein in glycogen synthesis
called glycogen synthase kinase 3 (GSK3). This

phosphorylation of GSK3 inhibits it action. GSK3 is a
protein which negatively regulates glycogen synthase (GS)
and is directly involved in the new synthesis of glycogen

from glucose.

So upon phosphorylation and subsequent

inactivation of GSK3 by Akt,

GS can retain its activity
18

to produce long chain glucose polymers of glycogen.

Akt

can also influence the transport of glucose from outside
the

cell

to

areas

within where

it

can be

broken down

and

utilized as an energy substrate. There is a specific
family of transporters that are responsible for glucose
movement within the cell.

transporters

(GLUTs).

They are referred to as glucose

In muscle and adipose tissue,

the

predominant isoform of the protein responsible for the
transport of glucose is Glut4.
activation,

This protein,

upon

translocates from an intracellular

compartment to the cell surface where it is incorporated

into the plasma membrane to facilitate glucose entering
the cell

(McCormick 1993).

Insulin can also stimulate a phosphorylation cascade
that involves the insulin receptor substrate but is

independent of the PI3K-Akt kinase pathway.

This pathway

is referred to as the extracellular-signal-regulated

kinase (ERK) transduction pathway.

The ERK pathway is

involved in numerous processes such as cellular

proliferation, differentiation,

and survival. After

insulin binds to the receptor tyrosine kinase it recruits
19

the insulin receptor substrate or IRS to the complex.
GRB-2,

a 23 kDa cytosolic accessory protein,

son of sevenless
domain.

(SOS)

recruits the

protein to the complex via its SH2

The SOS protein is a nucleotide exchange factor

that has an affinity for the SH2 domain of the Grb-2
protein due to its proline rich residues

(Nelson 2005).

Once this complex is formed it will recruit c-Ras to the
plasma membrane where it can bind GTP.

The SOS protein

helps facilitate an increased rate of binding of bound
GDP-Ras for GTP bound c-Ras.

The Ras superfamily of small

G proteins are highly conserved and exhibit GTPase
binding activity.
with GTP,

When Ras bound with GDP is replaced

a conformational change occurs.

This binding

activity usually functions similar to that of a molecular
switch with a whole host of activities ranging from

signal transduction,
messaging.

apoptotic prevention to secondary

When it comes to insulin signaling,

GTP bound

Ras can stimulate the mitogen activated protein kinase

pathway (MapK).

The first protein activated in this

cascasde is Map kinase kinase kinase

20

(Map3K)

or Raf-1.

The binding of Raf-1 and its activation by Ras stimulates
the phosphorylation of MEK on two Ser residues,

activating it.

MEK or Map kinase kinase

thus

(Map2K)

continues on through the signal cascade to phosphorylate
ERK or MapK at two distinct residues,
Once

ERK

is

activated

it

can

Thr0202 and Tyr204.

translocate

to

the

nucleus

where it can activate nuclear transcription factors like

Elkl.

Elkl is responsible for regulating the

transcription of over 100 insulin sensitive genes
2003;

(Parker

Parker 2004).
Fate

of

Glucose

Glucose entering the cell can be bound for multiple
fates.

There are four different distinct pathways glucose

can proceed down:

glycogenesis,

glycolysis,

pentose-phosphate pathway,

or the hexosamine biosynthesis pathway.

Typically,

upon insulin induction,

glucose is taken-

up and immediately converted to glucose-6-phosphate

by hexokinase or glucokinase

(G6P)

(liver). This step

represents a rate limiting or controlling step in
glycolysis.

Glucose-6-phosphate can proceed through the

glycolytic pathway which involves the catabolic breakdown
21

of glucose to pyruvate.

Pyruvate can function as a

substrate in numerous other metabolic processes.
Glucose-6-phosphate can also proceed along the
pentose phosphate pathway.

(PPP)

The pentose phosphate pathway

is a metabolic process that generates pentose

sugars but more importantly generates NADPH.
oxidative phase of PPP,

In this

G6P is converted to

gluconolactone-6-phosphate and eventually to 6phosphogluconate by G6PDH and gluconolactonase,
respectively.

6-phosphogluconate is then converted to

ribulose-5-phosphate by 6-phosphogluconate dehydrogenase.

This phase generates the two molecules of NADPH which can
be used for reductive biosynthesis as in fatty acid

synthesis.

The non-oxidative phase of the PPP pathway

involves the formation of ribose sugars used in nucleic

acid synthesis from Ribulose-5-P. Other end products of

this pathway are able to feed right into glycolysis.
Glycogenesis or glycogen biosynthesis is the

production of glycogen from glucose entering the body.

After glucose is converted to G6P by glucokinase it is
then converted to glucose-1-phosphate
22

(G1P)

by

phosphoglucomutase.

G1P is now converted to UDP-glucose

by UDP-glucose pyrophosphorylase.

This molecule of UDP-

glucose can be directly added to the non-reducing end of

a growing chain of glycogen branches by glycogen
synthase.
Hexosamine Biosynthesis Pathway (HBP)

Glucose-6-phosphate can also proceed down the
hexosamine biosynthesis pathway to generate UDP-GlcNac
(Figure 6).

(FGP)

G6P is converted to fructose-6-phosphate

by phosphofructoisomerase.

F6P can now be shunted

through the hexosamine biosynthesis pathway instead of
glycolysis and be converted to glucosamine-6-phosphate by
an enzyme called glutamine:fructose-6-phosphate
amidotransferase or GFAT.

GFAT is the rate limiting step

in the HBP and therefore controls entry of glucose within

the pathway. Glucosamine-6-phosphate can continue on
through the pathway forming a uridine diphosphate N-

acetyl glucosamine or UDP-GlcNAc.

UDP-GlcNAc can be used

in the production of various glycoproteins,
proteoglycans and gangliosides.

In the HBP there are two

enzymes that regulate all post-translational
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glycolipids,

modifications involving these O-GlcNacylation events.
The first enzyme is O-GlcNAc transferase or OGT.

OGT is

responsible for the reversible O-linked GlcNacylation on
numerous substrates such as transcription factors like
Spl and glycogen synthase

(Andreozzi 2004)

and other

enzymes involved in insulin signaling like IRS-1
2002)

and the glucose transporter Glut4

(Buse

(Marshall 1991).

It is interesting to note that GlcNacylation sites are

typically on or near sites known to be phosphorylated.
This can be problematic when these phosphorylation sites
which are necessary for the insulin signaling cascade to

proceed are occupied or sterically hindered by the
presence of a GlcNac moiety.

The other enzyme involved in

the O-linked GlcNacylation events is O-GlcNacase.

This

enzyme is solely responsible for the removal of the posttranslational modification

of

GlcNac

of

various

substrates(Fantus 2006).

The hexosamine biosynthetic pathway is up-regulated
when circulating levels of glucose within the body are

high,

which is the case for people with diabetes.

Marshall

et

al

showed that

there was
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indeed a

In 1991

correlation

between excess glucose flux being shunted through

hexosamine biosynthesis pathway and eventual insulin
resistance and or desensitization of the glucose

transport system (Marshall 1991).

In this study high

levels of insulin and glucose in the presence of
glutamine could cause impairment of glucose transport.

Furthermore glucosamine can enter the hexosamine
biosynthesis pathway distal to GFAT and cause that same

impairment with glucose transport

(Rossetti 1995). Since

then numerous labs have shown that glucosamine can induce
insulin resistance in a variety of model

(Fulop 2007)

(Virkamaki 1997)

by bypassing the rate limiting step GFAT

which controls the flux through the HBP.

It could also be that the end products of this

pathway are believed to be involved in altered gene
expression and maybe a mechanism responsible for some of
the disease states associated with Type II diabetes

mellitus.

High levels of UDP-GlcNAc generated through

the HBP pathway is believed to be involved in the up-

regulation of O-linked GlcNAcylation events which can
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post-translationally modify proteins involved in gene
transcription.
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Figure 6- Hexosamine Biosynthesis Pathway. (McNeill 1992;
Berg 1995). Copyright permission obtained from Oxford
University Press provided by Copyright Clearance Center.
(License # 2911400491159)

As indicated previously,

the addition of glucosamine

creates a pseudo-flux through the hexosamine biosynthesis

pathway and ultimately provides an altered state similar
to that of Type II diabetes.

This is the insulin

resistant state that we adapted for use throughout this
thesis.
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Insulin resistant states such as type II diabetes or
NIDDM are typically treated with insulin injections that
can be cumbersome and painful to the patient trying to

control diabetes.

The injection site for insulin

delivery is in the abdomen and it can be challenging.
Bruising,

skin irritation,

insulin leakage from injection

site as well as forgetting to even take the insulin
injection are all common problems.

For this reason a

compound that can be administered orally and mimic the

effects of insulin are highly sought after in the medical
world.

Vanadium:

An

Insulin Mimetic

Numerous types of insulin mimetic compounds have

been introduced for study.

These include various forms

of vanadium (Poucheret 1998),

and even chromium (Wang 2010).

selenium (Stapleton 1997)

Vanadium has a long

history of discovery and rediscovery.

Vanadium was

originally discovered by a mineralogist,

Del Rio in 1813

and so named it panchromium due to its formation of
various colored complexes formed at different oxidation

states(Arya 2011). Later in 1831, a chemist, Nils Gabriel
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Sefstom rediscovered vanadium and

Germanic goddess of beauty,
(Crans 2005).

0, +11,

and vanadate

aerobic

(V)

conditions

anerobic conditions,

a

+III,

+IV,

and +V. The

forms are the predominant

the

vanadate

(Rehder 2008).

form exists.

Under

like those similar to that of the

interior of a cell i.e.

exists.

for

youth and luster "Vanadis"

structure in solution at physiological pH
Under

it

Vanadium exhibits numerous oxidations

states ranging from -I,
vanadyl(IV)

so named

the cytoplasm,

Inside the cell, vanadate (V)

the vanadyl ion

in the form of V02+

is reduced to V02+ by reducing agents such as NADH and
glutathione

(Smith 1988).

Vanadium is a group V transition metal and is found

in relatively low abundance in the earth crust
There

are

over

60

different

minerals

that

(0.02%).

contain

vanadium as well as many known vanadium containing

compounds including "vanadoenzymes" or haloperoxidases
from marine algae and a vanadium containing cofactor
involved in nitrogenase activity in Azotobacter
chroococcum

(Smith 1988).

In mammals vanadium is a trace

element found in many dietary foods in relatively low
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amounts.

The total body pool of vanadium was determined

to be around 100 ug and that accumulation of vanadium
could be found in muscle,

bone,

such as liver and kidneys

(Byrne 1978).

vanadium is

essential

considered

an

fat and other tissues

trace

In some cases
element

and can

be linked to cell growth and reproductive fitness
(Ramasarma 1981).
Vanadium has

been

used

in vitro

and whole

animal

models with insulin mimetic like effects ranging from
increased glucose uptake and glucose oxidation,
inhibition of lipolysis,

(Pugazhenthi 1991)
(Rossetti 1989).

increased lipogenesis

and increased synthesis of glycogen

Vanadium has also been shown to mimic

insulin at the gene expression level by down regulating

new glucose production in the liver by influencing

pyruvate kinase in primary rat hepatocytes in culture
(Miralpeix 1991) and phosphoenolpyruvate carboxykinase
(PEPCK)

in rat hepatoma cells

(Bosch 1990).

One of the major contributing insulin like effects of
vanadate is its ability to normalize blood glucose

(Meyerovitch 1987) and enhance glucose transport in
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numerous tissue types such as adipocytes
skeletal muscle
and liver

(Okumura 1992),

(Brichard 1993).

(Shechter 1980) ,

brain (Meyerovitch 1989),

Vanadate was also shown to

normalize lipogenic enzymes such as G6PDH,

Acetyl-CoA

carboxylase, malic enzyme and ATP citrate lyase
indicating that these actions are similar to insulin
mediated pathways

(Khandelwal 1995).

Vanadium and vanadium salts

have

been

used to

the symptoms of diabetes since as early as 1899.
study,

treat

In this

Lyonnet and Martin published an article in La

Presse Medicale,

roughly translated as the therapeutic

uses of vanadium derivatives

(Lyonnet 1899).

However it

was years before vanadium was again studied in this
capacity.

More recently vanadium and vanadium salts have

been shown to stimulate glucose transport.

Tolman et al.

was the first to show that glucose oxidation and

transport in rat adipocytes was altered upon treatment
with vanadate

(Tolman 1979) . Many studies since then have

shown that in cell types such as muscle and adipose
tissue,

vanadate has a positive effect on glucose

transport.

Interestingly enough,
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this positive up

regulation was shown to be independent of the insulin

receptor substrate 1 or IRS-1 phosphorylation (Green
1986).

In another study,

it was also concluded that the

orthovanadate mechanism of

action

lies

downstream of the insulin receptor.
that

after

diaphragm,

in vivo

administration

of

distal

or

It was determined
vanadate

in mice

no increase in activation of the IR was

detected (Strout 1989).

Another group demonstrated that

the IR activity was not affected in liver and muscle when
STZ rats were treated with vanadyl sulfate for a period
of 9-12 weeks(Venkatesan 1991).

However one group had

conflicting results showing that vanadate enhanced
phosphorylation of the IR in rat adipocytes

(Tamura

1983) .

Somehow activation of the Glut 4 transporter and its
activity is increased upon treatment with vanadate.
wasn't

until

1985

that

the

true

effectiveness

It

of vanadate

was realized when Heyliger et al demonstrated that STZ

(streptozotocin)

diabetic induced female wistar rats

treated over a period of 4 weeks with sodium
orthovanadate showed normalized blood glucose levels
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despite low plasma insulin levels compared to that of the
control

(Heyliger 1985). Additionally,

vanadate restored

male wistar STZ induced hyperglycemic rats to a state
similar to that of normoglycemia

(Sun 2000).

Some speculate that the action of vanadate is

through inhibition of protein tyrosine phosphatases

(PTPases)

including one that is responsible for

deactivation of IRS-1.

If IRS-1 remains phosphorylated,

then the activation of downstream targets ie PI3K and Akt
retain signaling cascade induction.

It has been shown

that sodium orthovanadate in primary rat hepatocytes in
culture

can

influence

or

inhibit

the

function

of

the

Src

homology 2 domain responsible for signal transduction
(Pugazhenthi 1995).

Khandelwal et al also showed that

PTPase activities in obese Zucker fatty rat livers were

significantly decreased in rats treated with vanadate
(Pugazhenthi 1996).

John McNeill's group demonstrated

that bis-maltolato oxovanadium (IV)

of the enzyme

(PTP1B)

inhibits the activity

responsible for de-phosphorylation

of tyrosine residues on the insulin receptor (IR) in
Zucker fatty rat skeletal muscle
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(Mohammad 2002).

All of

these papers suggest that vanadium and its salts can be
used for therapeutic benefits in the tissues associated

with insulin resistance.

As with any positive outcome

negative aspects such as toxicity,

needs to be evaluated.

Vanadium and Toxicity

Vanadium has been shown to have many beneficial and
therapeutic effects with regards to insulin action.
However,

there is a great deal of evidence to suggest

that vanadium is toxic with increasing concentration and
increasing valance states

(Llobet 1984).

effect

in

of

sodium vanadate

humans

was

The most common
mild

gastrointestinal discomfort when administered to IDDM and

NIDDM patients at 125 mg/day.
in human trials,

It was also reported that

a tolerance of 75-300 mg doses of

vanadyl sulfate for 6 weeks in NIDDM patients was
observed

(Goldfine 2000).

Furthermore,

insulin

sensitivity in these NIDDM patients showed improvement

for 2 weeks following the halting of treatment
2000).

(Goldfine

Sodium orthovanadate was shown to be toxic at a

concentration of 2 mM in isolated perfused rat livers.
Vanadate treatments showed a release of cytosolic
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glutamate-pyruvate-transaminase

dehydrogenase

(GPT)

lactate

(LDH) and mitochondrial glutamate

dehydrogenase (GLDH) enzymes as well as a large decrease
of hepatic glutathione

(Younes 1991).

GPT and GLDH are

used as a clinical diagnostic measurement of hepatocyte
injury and overall health so these findings do indicate
liver toxicity.

LY294002

Inhibitor of PI3K

Lilly Inhibitor 294002 or 2-(4-Morpholinyl)-8phenyl-4H-l-benzopyran-4-one is a reversible inhibitor of
phosphatidylinositol-3-kinases
a derivative of morpholine,

(Vlahos 1994).

LY294002 is

a common additive in fossil

fuels and nuclear power plants as well as an emulsifier
in shellac based waxes for fruit preservation
1999).

(McGuire

It was shown that LY294002 had no effect on the

tyrosine phosphorylation of the IR or IRS-1 in 3T3 mouse
fibroblast over-expressing human insulin receptors
(Sanchez-Margalet 1994).

The LY294002 was used

successfully to inhibit downstream actions of PI3K such
as Akt(Jiang 2010).

It has been shown that Akt can

function in a number of pathways including apoptosis and
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survival mechanism.

In many types of cancer,

the Akt

pathway is commandeered by the cancer metabolism to
overcome the normal signal for cell death.

It has been

observed that many forms of cancer such as gastric,

cell,

ovarian(Shayesteh 1999)

renal

and lung cancers have

constitutively activated pathways involving PI3K/Akt.

History of Hepatocyte Isolation

In 1951 the notion of isolating primary liver cells
from adult Sprague-Dawley rats became evident
1953).

(Anderson

However the isolation to do so was crude and

ineffective yielding only 5% of to total starting
material.

Later in 1953 the method was perfected by

identifying substances such as citrate,

pyrophosphate,

versene or ethylenediaminetetraacetic acid (EDTA),

and

ATP additions to perfusion medium had equally beneficial
effects

(Anderson 1953).

the liver,

Upon blanching and perfusion of

the liver was then processed by pressing the

tissue in a Pyrex homogenizer tube via lucite pestal and

then pressing it through "bolting silk." The eventual
isolation yielded only 40-60% of the actual tissue
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started with.
the

liver

This mechanical force needed to separate

cells

from the

"cement"

is

believed

to

result

in damage to the cells and loss in total cells harvested.
In 1967,

Howard et al discovered that the use of

collagenase,

a collagen digestive enzyme,

to disrupt

cellular cohesiveness of the liver slices ultimately

yields intact liver cells at much higher viability
(Howard 1967).

It wasn't until much later in 1969 when Berry and

Friend developed a re-circulating perfusion method that
used collagenase and hyaluronidase buffer solutions.

That

method also employed the use of shaking and filtration of
digested liver through nylon mesh gauze

(Berry 1969).

Several years later a breakthrough was made in the
isolation technique.
concentrations

It was found that 5 mM

of calcium 2+ ion is

needed for effective

dispersion of the liver tissue (Seglen 1973) and in fact
it was a requirement of the collagenase. Since this time
hepatocyte isolation and the frequency of success has
increased dramatically.

Numerous laboratories employ the
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use of this technique,

each with their own modification

for improved isolation i.e.

"trade secrets."

Objective of the Study

The specific aim of this study was to continue to
evaluate the ability of glucosamine to induce an insulin

resistance state in primary rat hepatocytes.
Furthermore,

we hypothesized that the insulin mimetic

sodium orthovanadate could overcome this glucosamine
induced insulin resistant state. Our question became,

can

sodium orthovanadate stimulate key signaling proteins
similar

to

the mechanism of

action

of

insulin

in

a

normal

state when glucosamine is present.

Specific Aims of the Study

1.

Determine effects of glucosamine on the activity or

phosphorylation state of key metabolic enzymes in
the insulin signaling cascade and establish insulin
resistance.

2. Determine whether or not
orthovanadate

can

the

insulin mimetic sodium

circumvent

insulin resistance and
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restore insulin signaling in key metabolic enzymes
shown to

be

insulin

resistant.

3. Use the inhibitor LY294002 to potentially elicit
mechanistic

action

of

sodium orthovanadate.

CHAPTER

MATERIALS

II

AND

METHODS

Materials

Sodium orthovanadate,

glucosamine-HCl, heparin

sodium salt from porcine intestinal mucosa

(158 U/mg),

Waymouth MB 752/1 medium,

hyaluronidase (801 U/mg)

bovine tests,

N,N'-(1,2 Dihydroxyethylene)

acrylamide,

bisacrylamide,

sodium chloride,

potassium chloride,

phenol red,

from Sigma Aldrich

calcium chloride,

sodium dodecyl sulfate,

tetramethylethylenediamine
(APS),

from

(TEMED),

sucrose,

ammonium persulfate

and fructose were purchased

(St. Louis,

MO).

Collagenase type IV

(272 U/mg)

was obtained from Worthington Biochemicals

(Lakewood,

NJ).

Porcine insulin was obtained from Eli

Lilly (Indianapolis,

IN).

The Phototope-HRP Western Blot

Detection System which includes Anti-rabbit IgG,

linked antibody,

HRP-

biotinylated protein ladder along with

Lumiglo detection reagents A and B were obtained from
Cell Signaling Technology,

Inc (Danvers,

p44/42 MAPK (Erkl/2)(Thr202/Tyr204)
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MA).

antibody,

Phospho-

phospho-Akt

(Ser473)
(Ser21/9)

rabbit monoclonal antibody and Phospho-GSK-3a/(3
(D17D2)

Rabbit mAb were obtained from Cell

Signaling Technology,
Antibody (Tyr 989)

Inc (Danvers,

(sc-17200-R)

MA).

Phospho-IRS-1

rabbit polyclonal

antibody were obtained from Santa Cruz Biotechnology.
Supplies for cell culture include Dulbecco's Modified

Eagle Medium (DMEM) which contains 1,000 mg/L D-glucose
and 110 mg/L sodium pyruvate,

but no L-glutamine or

phenol red (Gibco). Materials and supplies for Western
blot analysis include SeeBlue Plus2 protein standard,
NuPAGE LDS sample buffer,
Buffer (25X),

Novex Tris-Glycine Transfer

Novex 10% Tris-Glycine and 4-12% Bis-Tris

Mini Gels 1.0-1.5 mm,

10 well gels.

iBlot system with

iBlot transfer stacks regular nitrocellulose and

polyvinylidene fluoride (PVDF) 0.2 uM pore size membrane
(Invitrogen).

Kodak Biomax XAR film (8 in x 10 in)

(Sigma) was used to image chemiluminescence of bound
antibodies reacting to substrate in immunoblot assay.
Falcon tissue culture dishes

(60mm x

15mm)

round

polystyrene vacuum gas plasma treated culture plates

40

(Becton Dickinson)

were used to culture primary rat

hepatocytes.
Cell

Male Sprague Dawley

Culture

(SD)

housed in an approved (IACUC)

Michigan University (WMU).

rats

(Charles Rivers)

were

animal facility at Western

SD rats were feed Lab Diet

5001 standard rat chow and drinking water ad libitum. The

rats were housed one per cage on a 12 h light/dark
schedule.

SD rats weighing approximately 200-400 grams

were food deprived two days prior to surgery.

The rats

were anesthetized through an injection into the
peritoneal cavity with approximately 35-50 cc of

pentobarbital sodium salt depending on overall weight
(45-50 mg/kg).

Perfusion and digestion of the liver was previously
described (Wagle 1998).

The liver is cut into many

pieces and placed onto sterile gauze covering a 600 mL
beaker.

The digestion solution is poured over the tissue

which is then pushed through gauze to isolate primary
liver cells within the digestion solution.

Approximately

300 mL of cell suspension/digestion solution are poured
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into six 50 mL conical tubes and spun for 3 mins at

lOOxg.

The media is then aspirated leaving the mass of

cells behind.

Cells are then resuspended in Waymouth

serum free media + BSA,
volumes

and

concentrated into two smaller

transferred to

50

mL

concical

tubes.

Once

again the cells are spun for 3 mins at lOOxg and media
aspirated.

Cells are then resuspended in Waymouth media

and washed for a third time using the same process stated
above.

The primary rat hepatocytes are combined into one

conical tube and suspended in 5-10 ml of media depending
on the size of the pellets.

Cells can now be counted and

plated.
Trypan Blue Exclusion

Viable cells are counted using a hemocytometer and

the trypan blue exclusion method (Tennant 1964). The

trypan blue is able to penetrate the compromised cells
due to membrane disruption therefore viability can be

determined.

Once the viability and number of cells is

determined,

cells are plated to yield a confluence of 90%

or greater if possible.

not used.

Cells below 70% viability are

Typically, between 2.0-3.0 x 106 cells per
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plate are used.

The primary cells are plated on

collagen-coated plates which allows for cell adherence in
Waymouth media with the addition of BSA.

After 4 hrs the

media is changed to a BSA free Waymouth serum and left

for 18 hrs prior to treatment in a 37°C humidified
incubator containing 5% CO2.
Preparation of

(lOx)

Perfusion and Digestion Solutions

The perfusion lOx solution is made by combining 43.5
g NaCl,

12.0 g HEPES,

15.0 g Fructose,

0.95 g EGTA or

ethylene glycol-bis(2-aminoethylether)-N,N,N',N'
tetraacetic acid.

-

The volume is brought to 450 mL along

with the subsequent addition of 6 mL of a 0.5% Phenol red

solution.
NaOH,

Solution is then brought to a pH of 7.4 with

diluted to 500 mL and passed through a 0.22 urn

sterile

filter.

The digestion lOx solution is made by combining 2.5
g KC1, 41.5 g NaCl,
15.0 g Fructose.

12.0 g HEPES,

3.7 g CaCl dihydrate,

The volume is then brought to 450 mL

along with an addition of 6 mL of a 0.5% Phenol red
solution.

The solution is then brought to a pH of 7.4
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with NaOH,
sterile

diluted to 500 mL and passed through a 0.22 urn

filter.

Preparation of (lx)

Perfusion and Digestion Solutions

The perfusion lx solution is made by diluting the
lOx

stock.

30 mL

of

diluted to 250 mL.

the

lOx

stock solution

is then brought to a pH of 7.4,

This solution

diluted to 300 mL and

passed through a 0.22 urn sterile filter.
C

taken and

To this solution an anticoagulant

heparin sulfate is added at 10 Units/mL.

incubated at 37°

is

Solutions are

in a water bath.

The digestion lx solution is made by diluting 50 mL
of the lOx stock to 450 mL along with the addition of 3%

BSA,

93 Units/mL of hyaluronadase from bovine testes,

Units/mL of trypsin inhibitor.
is brought to a pH of 7.4,

The lx digestion solution

diluted to 500ml after the

addition of the tissue digestive enzyme Type IV

collagenase at a final concentration of 100 Units/mL.
The solution is then passed through a 0.22 urn sterile
filter and incubated at

37°C in a water bath.
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Preparation of Collagen Coated Tissue Culture Plates

Rat tail collagen is diluted from a stock

concentration ranging from 4.0-5.0 mg/mL down to 0.2

mg/mL.
added

1 mL of the diluted collagen solution is then
to

60

mm x

15

mm

round

tissue

culture

dishes

that

have been vacuum gas plasma treated by the manufacturer.
The

solution

is

swirled and

approximately 2-3 mins.

allowed to

sit

for

This step is repeated following

removal of the collagen solution.

Plates are allowed to

dry overnight in the Baker biological safety cabinet
under UV light.
Treatment

Schedule

Primary rat hepatocytes are either cultured in DMEM

low glucose media or with DMEM low glucose media + 1 mM

glucosamine.

After an 18 hr incubation in glucosamine,

the cells are used to study insulin resistance.

Cells

that were not incubated in DMEM + glucosamine were used

as the normal control model for purposes of comparison.
(N)

= no addition,

nM)

Insulin

(G)

= (1 mM)
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glucosamine,

Ins = (80

Table 1- Treatment Schedule of Primary Rat Hepatocytes
S amp1e

Treatment

N.Na

DMEM low glucose media

for

24

hrs.

N.Ins

DMEM low glucose media

for

24

hrs.

+

mM

glucosamine for

(80nM)
G.Na

Schedule

Insulin

at hr 23.

DMEM low glucose media

1

24hrs.

G. Ins

N.500.1

DMEM low glucose media + 1 mM glucosamine for 24
hrs. Insulin (80nM) at 23 hrs
DMEM low glucose media
uM)

G.500.1

DMEM low glucose media

G.LY.500.1.1

24

+

hrs.

Vanadate

(500

1

mM

glucosamine for

at

18

hrs .

DMEM low glucose media

for

24

hrs.

uM)

(80nM)

at

+

24hrs.
N.LY.Ins.1

for

at 18 hrs.

Vanadate

at 22 hrs.

(500uM)

Insulin

DMEM low glucose media
24hrs.

LY294002

uM)

18rs.

at

(50 uM)
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23

LY294002

(50

hrs.

1

mM

glucosamine for

at

17

hrs.

Vandate

(500

BCA Protein Assay

Protein concentrations were determined using the
Pierce BCA protein assay kit. The BCA protein assay
employs the reagent bicinchoninic acid. The reagent forms
a copper complex which exhibits strong absorbance. The

protein/copper complex absorbance is measured
spectrophotometrically at 562 nm wavelength and is
proportional to the amount of protein present. A series
of BSA standard solutions ranging from 25-2000 ug were

made with the provided 2 mg/mL stock solution of BSA.
These

were

standards

used

to

and

create

their measured

a

standard

absorbance

curve

to

at

determine

562

nm

unknown

protein concentration in whole cell lysates from the

treated primary rat hepatocytes.

Concentrations were

determined by employing the protocol above.

This protein

assay and its procedure were originally described in a
paper by Smith et al

(Smith 1985).

SDS-PAGE

Sodium dodecyl sulfate poly acrylamide gel
electrophoresis

(SDS-PAGE)

employs the use of a strong
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detergent and a separating matrix composed of acrylamide
and bisacrylamide chemically crosslinked.

This

polymerization is catalyzed by the addition of TEMED or
tetramethylethylenediamine and ammonium persulfate

(APS).

APS is a strong oxidizing agent that creates radical
species which facilitate the polymerization.

SDS is a

strong detergent that denatures the protein from it

tertiary and quartnary structures down to the primary
protein structure of single amino acids bound by

polypeptide bonds.

This detergent also coats the protein

in an overall negative charge.

This allows for the

separation of all the proteins in the whole cell lysate
to be solely based on the molecular weight.

Since the

proteins are negatively charged they will migrate toward
the positive cathode in a polyacrylamide gel matrix.
SDS-PAGE is composed of two layers:

separation gel.

The

a stacking gel and a

The stacking gel typically contains only

4% polyacrylamide while the separting gel was composed of
10-12% based on protein of interest.

Latter studies

employed the use of pre-poured gels from Novex and
consisted of 10% Tris-Glycine or 4-12% Bis-Tris.
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Western Blot Analysis

Upon separation of whole cell lysate/ protein slurry
via SDS-PAGE,

the proteins are transferred to a

nitrocellulose membrane.

This technique is performed in

an electroblotting apparatus with Tris glycine transfer
buffer or an iBlot western blotting transfer system. Once
protein has been transferred to this membrane,

analysis can begin.

immunoblot

The membrane is first incubated in

0.1% non-fat dry milk in Tris buffered saline + Tween 20

(200 mM Tris Base,

150 mM NaCl,

0.05% Tween-20,

pH 7.6)

(TBS-Tween) overnight at 4°C with gentle agitation to
saturate non-specific binding sites.

The membrane is

then incubated in primary antibody overnight at 4°C with
gentle agitation.
membrane

is

Once the primary antibody is bound,

washed

3x

in

TBS-Tween

for

5-45

mins.

the

The

membrane is then incubated in a secondary (2°) antibody
which contains horseradish peroxidase (HRP)

linked anti-

rabbit IgG and HRP-linked anti-biotin antibodies. After

incubation in 2° antibody, the membrane is again washed
3x

in TBS-Tween

for

5-45 mins.

A

luminol

substrate

containing hydrogen peroxide is added to the membrane
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causing a chemiluminescent reaction which emits light.
The luminol is converted to 3-aminophthalate in the
presence of hydrogen peroxide to produce photons of

light.

This emitted light is due to 3-aminophthalate

decaying from an excited triplet state to a lower energy
level. This radiation or light can be captured on XAR
film.
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CHAPTER

RESULTS

AND

Effect of Glucosamine

III

DISCUSSION

on

Insulin

Induced IRS-1

Phosphorylation
In an insulin resistant state,

the addition of

insulin is no longer able to stimulate the

phosphorylation cascade of key proteins that are part of
the insulin signal cascade or at least not to the same
extent

that

is

observed under

normal

study,

we utilized glucosamine,

conditions.

In

our

a substrate that enters

the hexosamine biosynthesis pathway downstream of the

rate limiting enzyme GFAT to mimic excess glucose in the

system and flow through this pathway to generate an
insulin resistant model in primary rat hepatocytes.

If insulin resistance is generated then insulin
should no longer be able to stimulate to the same extent
as

insulin under normal

condition the

increase

in

phosphorylation of a key signaling protein in the insulin
signal cascade,

IRS-1.

As shown in Figure 7, the
51

addition of 80 nM insulin to primary rat hepatocytes for
1 hr shows an increased phosphorylation of IRS-1 1.4 fold
over control as measured by western blot analysis.
Incubation of these cells with 1 mM glucosamine for 24
hrs has no significant effect compared to the cells with
no addition.
of

80

nM

In the presence of glucosamine,

insulin

for

one

hour

was

not

able

to

the addition
increase

the phosphorylation of IRS-1 compared to the cells
treated with insulin alone.
confirmed.

Glucosamine

alone

Thus,
had

insulin resistance was
no

toxic

effects

cells as no morphological changes were observed.
shows the effectiveness of the compound,

on

the

This

glucosamine,

to

induce a model for insulin resistance for further study.
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Figure 7 - Effect of glucosamine on insulin induced IRS-1
phosphorylation.
Primary rat hepatocytes were incubated
in DMEM low glucose media without (N) or with (G) 1 mM
glucosamine for 24 hrs. Cells were either treated with 80
nM

Insulin

(Ins)

after

23

hrs

or

left

untreated

(NA) .

Cells were processed, with whole cell lysate collected.
The results are expressed as the mean ±SEM of N number of
animals used for each experiment. The difference between
nontreated

and

treated

tailed student's t test.

cells

were

Statistical

evaluated

by

significance

one

-

* was

tested at p<0.05.

Effect of Sodium Orthovanadate on Glucosamine Induced

Insulin Resistance and the Phosphorylation of IRS-1

Insulin resistance continues to be a growing medical

issue world-wide.

It is important to not only understand

possible mechanisms that cause the disease but also
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explore new avenues of treatment.

Insulin mimetics are

naturally occurring compounds that have been used for
over a century.

With these insulin mimetics and model of

insulin resistance,

through the use of glucosamine,

the

signaling pathway and the mechanism of action for the
insulin mimetic

demonstrated,

vanadate

can be

studied.

As

was

insulin increased the phosphorylation

nearly 1.5 fold of the key signal protein IRS-1 when
compared to the control

(Figure 7).

However,

when

glucosamine is added to establish the insulin resistant
state the effects of insulin to stimulate phosphorylation
of IRS-1 is markedly decreased.
insulin mimetic

As seen in Figure 8, the

sodium orthovanadate was

able

to mimic

the effects of insulin in the cells without glucosamine
treatment by increasing the phosphorylation of IRS-1.
Furthermore,

it was also able to increase the

phosphorylation of IRS-1 in the cells treated with
glucosamine.

In the non-diabetic model,

cells treated

with LY294002 an inhibitor of PI3K a downstream protein

of IRS-1,

insulin showed little to no effect on IRS-1

phosphorylation.

This result was unexpected.
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Since this

inhibitor works downstream of IRS-1,
treatment

with

LY294002

and

it was expected that

insulin would

show an

increase in phosphorylation similar to that of insulin
alone. Also,
cells

in the glucosamine induced diabetic model,

treated with

LY294002

and

vanadate

showed

a

marked

decrease compared to that of the no addition non-diabetic
control.

Thus,

unexpected,

while the effect of LY294002 was

vanadate and insulin in the presence of this

compound mirrored each other.
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Figure 8- Effect of sodium orthovanadate on glucosamine
induced insulin resistance and the phosphoryation of IRS1 TYR989. Primary rat hepatocytes were incubated in DMEM
low glucose media without (N) or with (G) 1 mM
glucosamine for 24 hrs and treated with 500uM sodium
orthovanadate (500.V) added at 18 hrs. Cells were either
treated with 80 nM Insulin (Ins) after 23 hrs, LY294002
(LY) or left untreated (NA).
LY294002 was added 1 hr

prior to Ins or Van.
Cells were lysed and processed with
whole cell lysate collected.
The results are expressed
as

the mean

+SEM of N

number

of

animals

used

for

each

experiment. The difference between nontreated and treated
cells were evaluated by one -tailed student's t test.

Statistical significance * was tested at p<0.05.
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Effect of Sodium Orthovanadate on Glucosamine

Induced

Insulin Resistance and the Phosphorylation of GSK3P
It has been shown that phosphorylation on Ser 9 of

GSK3(3 by the insulin signaling cascade is the underlying
mechanism of its inhibition

1999).

(Sutherland 1993)

In the case of insulin resistance,

(Summers

the ability of

insulin to stimulate the synthesis of new glycogen in the
liver

and muscle

is

diminished.

Insulin

fails

to

elicit

a normal function and promote glycogen synthesis. Any

compound that could restore this function could represent

a possible therapeutic target. Many labs have implicated
an insulin mimetic effect of vanadate on restoring

glycogen synthesis in a variety of tissues

(Tamura 1984)

(Rossetti 1989)

(Pugazhenthi 1991)

(Khandelwal 1995)

(Semiz 2002).

We set out to determine if sodium

orthovanadate could restore the phosphorylation and

deactivation of glycogen synthase kinase.
Our results

indicate that

insulin was

able to stimulate

over a 2 fold increase in GSK3|3 phosphorylation when

compared to the control.

Sodium orthovanadate was also

able to increase phosphorylation of GSK3(3 almost 2 fold
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as well.

Interestingly,

the mimetic did not restore the

insulin resistant state.

The results for GSK3a are very

similar to what we observed with GSK3(3,

a lack of

phosphorylation induction in the glucosamine induced
insulin resistant

state.

The LY294002

inhibitor was able

to decrease the effects of the insulin induction compared
to the
model.

insulin stimulated induction in the non-diabetic

Figure 9- Effect of sodium orthovanadate on glucosamine
induced insulin resistance and the phosphorylation of
GSK3(3 Ser9. Primary rat hepatocytes were incubated in
DMEM low glucose media without (N) or with (G) 1 mM
glucosamine for 24 hrs and treated with 500uM sodium
orthovanadate (500.V) added at 18 hrs. Cells were either
treated with 80 nM Insulin (Ins) after 23 hrs, LY294002
(LY) or left untreated (NA).
LY294002 was added 1 hr

prior to Ins or Van.
Cells were lysed and processed with
whole cell lysate collected.
The results are expressed
as

the mean

+SEM

of

N

number

of

animals

used

for

each

experiment. The difference between nontreated and treated
cells were evaluated by one -tailed student's t test.

Statistical significance * was tested at p<0.05.
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Figure 10- Effect of sodium orthovanadate on glucosamine
induced insulin resistance and the phosphorylation of
GSK3a Ser21. Primary rat hepatocytes were incubated in
DMEM low glucose media without (N) or with (G) 1 mM
glucosamine for 24 hrs and treated with 500uM sodium
orthovanadate (500.V) added at 18 hrs. Cells were either
treated with 80 nM Insulin (Ins) after 23 hrs, LY294002
(LY) or left untreated (NA).
LY294002 was added 1 hr

prior to Ins or Van.
Cells were lysed and processed with
whole cell lysate collected.
The results are expressed
as

the mean

±SEM of

N

number

of

animals

used

for

each

experiment. The difference between nontreated and treated
cells were evaluated by one -tailed student's t test.

Statistical significance * was tested at p<0.05.
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Effect of Sodium Orthovanadate on Glucosamine Induced

Insulin Resistance and the Phosphorylation of Akt
Interestingly,
orthovanadate has

the insulin mimetic sodium

little to no

effect

on the

phosphorylation of Akt in the non-diabetic control state
or the glucosamine induced insulin resistant state.
Insulin was

able

to

increase the

induction of

phosphorylated Akt 1.8 fold over the no-addition control
at a concentration of 80 nM.

However,

when the cells were

treated with vanadate no significant increase in
phosphorylated Akt was observed using western blot
analysis.

The same results were obtained for a non-

diabetic model and treatment with sodium orthovanadate by
Mehdi et al.
CHO-HIR cells

(Mehdi 2005).

In this study the group used

(Chinese hamster ovary cells over-

expressing human insulin receptor)

incubated with 100 nM

insulin for 5 min or 1 mM of vanadium compounds for 10
min.

They demonstrated vanadium compounds such as

vanadyl sulfate,

BMOV induced phosphor-Akt Ser473

phosphorylation. However,

sodium metavanadate

(NaMV)

sodium orthovanadate did not illicit any response.
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and
It

appears that there is a difference in the action of

inorganic vanadium compounds like sodium orthovanadate
(used in this study)
BMOV.

and vanadium metal-organic such as

This phenomenon of higher potency of organic

vanadium compounds over vanadium salts has been observed
before

(Reul 1999). The data suggest that differences in

potency between compounds are due to differences in their

insulin-like properties.
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Figure 11- Effect of sodium orthovanadate on glucosamine
induced insulin resistance and the phosphorylation of Akt
Ser473. Primary rat hepatocytes were incubated in DMEM
low glucose media without (N) or with (G) 1 mM
glucosamine for 24 hrs and treated with 500uM sodium
orthovanadate (500.V) added at 18 hrs. Cells were either
treated with 80 nM Insulin (Ins) after 23 hrs or left

untreated (NA). Cells were lysed and processed with whole
cell lysate collected.
The results are expressed as the
mean

+SEM

of

N

number

of

animals

used

for

each

experiment. The difference between nontreated and treated
cells were evaluated by one -tailed student's t test.

Statistical significance * was tested at p<0.05.

Discussion

With 285 million cases worldwide a growing epidemic
of insulin resistance is in our "midst." Alarmingly,

the

number of new cases of diabetes in projected to increase
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to 435 million by the year 2030. According to the

International Diabetes Federation, a person dies every
seven

seconds

needed to

from diabetes.

combat

this

New and novel

disease

state.

treatments

are

Insulin and other

anti-diabetic agents are listed as the 4th most in
therapeutical class spending (Kleinrock 2011) . Human

insulins and synthetic analogues have contributed to 64%
of growth in this area with a 1.3 billion dollar increase

in total spending,

according to the IMS Institute for

Healthcare Informatics.

Individuals diagnosed with

insulin resistance are faced with a myriad of treatment
regimes.

Some are used alone or in combination with

daily injections of insulin,

painful.

which can be troublesome and

One of the more commonly prescribed anti

diabetic drugs is metformin. According to a report by the

IMS Institute (Kleinrock 2011), metformin was the 7th most
prescribed drug in the United States.
16.9 billion
medicines.

dollar

Other

increase

in oral

In 2010 there was a
anti-diabetic

anti-diabetic medication

Thiazolidinediones,

such

as

a class of glitazones drugs along

with sulfonylureas are two other commonly prescribed
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drugs to treat insulin resistance that helped to

contribute to the escalation in diabetic drugs being
used.

Other compounds,

such as naturally occurring or

synthesized molecules that contain transition metals,
have

been

observed to have

insulin mimetic

action.

While

these compounds have offered potential in alleviating
diabetic symptoms the basic science behind their
mechanism of

century,
and

action

still

remains

elusive.

For

over

a

scientists have implicated the use of vanadium

vanadium

salts

to

treat

numerous animal models.

insulin

resistance

in

In many cases glucose homeostasis

was corrected and symptoms were managed using vanadate
and its derivatives
Sekar 1996;
treatments

mimic

the

(Heyliger 1985; Meyerovitch 1987;

Crans 2005).
and the mode

actions

of

However the mechanism for these
of

action

insulin

that

remain

allows

unclear.

signaling is disrupted in patients with NIDDM.

vanadate

Insulin

In our

case we utilized the increased flux through the HBP

pathway to establish an insulin resistant state in

primary rat hepatocytes. Our question was to determine
65

to

the mode

of

action or

influence

vanadate

has

on the

insulin signaling cascade at key metabolic enzymes
1, Akt and GSK3)
could still

(IRS-

and determine whether or not vanadate

elicit

insulin resistant.

insulin like

action even in this

Previously in our laboratory,

established that glucosamine,

it was

in very low concentrations,

can induce an insulin resistant state in rat hepatocytes
(Sandhya 2011).

Our laboratory has a long standing

interest in not only understanding how insulin affects
key metabolic processes but also how insulin mimetics

might stimulate these same processes.
Vanadate

(Berg 1995),

In addition to

our laboratory has studied the

insulin mimetic selenium (Stapleton 2000;
2000).

Stapleton

Selenium has insulin mimetic properties that

increase PI 3-kinase activity in rat hepatocytes in
culture

(Stapleton 1998). Other evidence supports the

involvement

of MAPK and S6

kinases

in the

insulin-mimetic

actions of vanadium and selenium (Hei 1998).
al.

demonstrated similar results with MAPK.

Stapleton et
In this study

they demonstrated that both the p42 and p44 MAP kinases

66

are activated when either hepatocytes or adipocytes are
incubated in the presence of selenate (Stapleton 1997).
Other recent work from our laboratory demonstrated,
in primary rat hepatocytes,

that cells incubated with

selenium showed an increase the phosphorylation of Akt
Ser473 under glucosamine induced insulin resistance
similar to that observed with insulin alone conditions

(Sandhya 2011).

Since we have observed parallel results

with selenium and vanadate in previous studies,

it was

hypothesized that the insulin mimetic properties of
vanadium and

resistant

its

state

salts

could also

similar

test this question,

to

that

of

function

a

normal

in

a

insulin

state.

To

primary rat hepatocytes were isolated

using the heparin perfusion-collagenase digestion method
and vanadate and insulin were tested on key signal

proteins under control and glucosamine induced insulin
resistance

The

conditions.

first

use

of

vanadium as

an

insulin mimetic

was

demonstrated in the laboratory of Ruth Partridge in 1979
(Tolman 1979).

Her group demonstrated that vanadate could

stimulate glucose oxidation and transport in rat
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adipocytes.

Furthermore they measured an increase in the

radio-labeled glucose-14C conversion to glycogen-14C in
isolated hepatocytes and diaphragm sections.

It was also

determined that the uptake of tritiated 2-deoxyglucose in
rat adipocytes was increased 6-12 fold,

similar to that

of a maximally activating concentration of insulin
(Tolman 1979).
In

1983

Tamura

et

al

demonstrated

that

vanadate

was

able to stimulate glycogen synthase in a manner similar
to

that

of

insulin

in rat adipocytes.

but

not

identical

to

that

of

insulin

The group determined that vanadate

stimulated the phosphorylation of the insulin receptor on
tyrosine residues both in intact adipocytes and in
solubilized insulin receptor fractions.
This

showed that

insulin

and

vanadate

could

have

similar initial actions on receptor phosphorylation and

also act similarly on an intracellular event,
activation of glycogen synthase
1984).

such as the

(Tamura 1983; Tamura

Our results support these findings of vanadate

increasing glycogen synthase activation indirectly.
While we did not directly measure the phosphorylation of
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the insulin receptor in the presence of vanadate in our
cells,

the increase in phosphorylation of the IRS-1 could

be indicative of the phosphorylation of the receptor as
IRS-1 is downstream in the signal cascade. We showed that

vanadate could stimulate IRS-1 phosphorylation (Figure 8)
and downstream enzymes responsible for inhibiting
glycogen synthase was phosphorylated and thus inhibited
(Figure 9,10) .

Vanadate was able to stimulate the phosphorylation
and thus deactivation of glycogen synthase kinase 3 which
is responsible for inhibiting glycogen synthase.

Western

blot analysis of IRS-1 phosphorylation on Tyrosine 989
showed an increase upon treatment with 500 uM sodium

orthovanadate in the control model without the presence
of glucosamine.

IRS-1 phosphorylation also increased as

well in cells treated with 80nM insulin compared to that
of

the

no

addition.

This

demonstrates

that

insulin

and

vanadate have the ability to increase phosphorylation of
IRS-1

(Figure 9).

In contrast to these findings,

Shechter

et al has implicated a membranous non-receptor tyrosine
kinase that is involved with the insulin like response
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produced with vanadate (Elberg 1997).

Furthermore, they

also determined that the insulin mimetic response of
vanadate is independent of the actions of insulin via the

IR and IRS-1(Shechter 1995). The group used quercetin,
cell-permeable inhibitor of the IR,

a

to show that insulin

activation of the receptor was blocked and that vanadate

induced activation was increased even though the
inhibitor was present.

This activation was observed in

rat adipocytes and may not apply to rat hepatocytes and
the

action

of

Vanadate

within

these

cells.

During the 1980's all these effects of vanadium and
its ability to mimic the action of insulin were all
demonstrated in "in vitro" studies.

With the development

and the use of these compounds such as alloxan and

streptozotocin
rodents,

(STZ)

to induced diabetic models in

it became possible to look at "in vivo" models

for study.

STZ induced diabetes simulates a model of type

1 diabetes by destroying pancreatic beta cells
responsible for secreting insulin. One of the most
monumental and pioneering studies was introduced by the

McNeil group. They decided to administer sodium
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orthovanadate to the drinking water female wistar rats
(non-diabetic control)

4 weeks.

and STZ induced diabetic rats for

They showed that blood glucose levels after

treatment were not significantly different when compared

to non-diabetic rats despite low insulin levels in STZ
induced rats.

However,

diabetic rats that did not receive

the treatment had a blood glucose level that was three

times higher than the non-diabetic control group
(Heyliger 1985) .

The McNeill group also produced two separate papers
that concluded BMOV or bis(maltolato)oxovanadium

(IV)

had

insulin mimetic activities that are independent of

Akt/PKB.

In the first paper the group looked at changes

in PI3K expression and activity in rat skeletal muscle
from STZ-diabetic and fa/fa obese Zucker rats treated

with BMOV for 3 weeks. They determined that glucose
utilization was restored in the diabetic model with

vanadate but basal levels of PI3K as well as insulin

stimulated PI3K were unaffected by treatment with BMOV as

compared to the control. These results suggest that BMOV
does not influence or reduce hyperglycemia in a PI3K
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dependent manner

(Mohammad 2001) .

These results are

monumental to the field of study because all studies thus

far implicated PI3K in glucose uptake. The second paper
used STZ-diabetic rats and determined that chronic

treatments of BMOV normalized plasma glucose levels

without having an effect on PKB activity.

It was

concluded that the glucoregulatory effects of BMOV were

independent of PKB activity (Marzban 2001).

Thus there

is prior evidence to suggest that vanadate and its
insulin mimetic action and involvement in stimulation of

glycogen synthesis via inhibition of GSK3 could be

independent of Akt/PKB.

In contrast to these finding a group from the
Montreal

Diabetes

Research Center had observed a

different phenomenon.
vanadium compounds

This group observed that organ-

(OVC)

oxo-bis acetyl acetonate)

such as BMOV or VAC

(vanadium

were able to activate IRS-1,

Akt/PKB as well as GSK3(3 in Chinese hamster ovary cells
overexpressing human insulin receptor (CHO-HIR)

2005).

However,

consistent with our findings

(Mehdi

(Figure 11)

inorganic compounds such as sodium orthovanadate and
72

sodium metavanadate failed to exert any effect on Akt/PKB
phosphorylation (Mehdi 2005),

suggesting a different

mechanism for organic and inorganic variations of
vanadium.

If sodium orthovanadate is proposed to be an insulin
mimetic then it should perpetuate the same signaling
events

similar to

that

of

insulin.

Our

results

seemed to

indicate that the insulin mimetic agent sodium
orthovanadate is able to stimulate the phosphorylation
and inactivation of GSK3 independently of Akt
measured at Serine 473)
synthesis
It

(when

and thus activating glycogen

(Figure 8 and 9).

has

been

demonstrated

that Akt

dependent on two phosphorylation sites,

activation

is

Thr308 and Ser473

with the latter phosphorylation site being a requirement
for full kinase activity (Fayard 2005) . Akt has many

proteins and substrates that are subject to regulation by
its kinase activity including GSK3,
01

(FOXOl)

forkhead box protein

and tuberous sclerosis complex 1/2

mentioned earlier in the introduction,

(TSC2).

PDK1 controls the

phosphorylation of the Thr308 residue on Akt/PKB and a
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As

previously unidentified protein deemed PDK2 was thought
to be responsible for the Ser473 phosphorylation (Chan
2001; Dong 2005). New evidence has emerged that shows a

link to a nutrient sensing pathway involving the multiprotein complex mTORC2 to Akt phosphorylation at Ser473
(Sarbassov 2005).

Although relatively little is known

about this complex, many have demonstrated a clear link
between the mTORC2 complex and many biological processes

that include cell cycle progression,
metabolism.

cell survival and

The mTORC2 complex involves the master

regulator (mTOR)
of rapamycin,

mechanistic

rictor, mLST8,

(formerly mammalian)

target

mammalian stress-activated

protein kinase interacting protein (mSINl),

Protor-1 and

Deptor.

It was shown in 2005 that mTOR and the accessory

protein rictor were directly responsible for

phosphorylation of Akt at Ser473 in Drosophila and
numerous human cancer cell lines

(Sarbassov 2005).

More

recently another group demonstrated that mSINl was a

critical factor responsible for the stabilization of the
mSINl-mTOR-rictor complex ie mTORC2 and that complex is
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likely the sole "PDK2" or phosphoinositide-dependent
protein kinase 2 responsible for the Akt phosphorylation
at Ser473

(Jacinto 2006).

It was also shown that the

mTORC2 complex is involved in insulin signaling to FOXO
but not to TSC2 or GSK3B and it requires mLST8 and

rictor.

They demonstrated that mTORC2 complex is

involved in insulin signaling and subsequent activation
of Akt at Ser473 and that signal can be abolished by
disruption of the complex (Guertin 2006).

Furthermore,

that ablation of the complex did not disrupt insulin

signaling for GSK3

(Guertin 2006). This becomes very

significant due to the fact that many groups have
implicated the phosphoserine 473 on Akt as a marker for
insulin signaling and activation of GSK3.

Due to a lack

of an increase in Akt phosphorylation by treatments with

sodium orthovanadate and a response by signaling proteins
upstream and downstream of the major metabolic regulator
we began to question the validity of these findings
(Figure 11).

However,

experiments with inhibitor LY294002

which were intended to shed light on the mechanistic
action

of

vanadate

were

inconclusive.
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In

conclusion

vandate was able to stimulate key signaling proteins in
the insulin signaling cascade similar to that of insulin.
However,

the mechanism of action for vanadate is

different with respect to insulin inducing
phosphorylation at Akt-Ser473 and vanadate did not.
Vanadate

and

Insulin has

similar

effects

on

the

insulin

receptor substrate IRS-1 Tyr989 and GSK3a/(3 Ser21/9.

The

future direction of this study should investigate the
activation of mTOR along with all the components of the

mT0RC2 complex in a diabetic model of glucosamine induced
insulin resistance and vanadate.

The mT0RC2 complex has

been shown to phosphorylate and activate Akt on Ser473.
Vanadate may interact in some way with this multi-protein
complex and cause downstream effects circumventing the
insulin

resistant

state.

76

APPENDIX

stern Michigan University
Institutional Animal Care and Use Committee
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To:
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From: Robert Eversole, Chair
Re:

IACUC Protocol No. 10-02-01

Your protocol titled "Regulation ofGene Expression in Hepatocytes" has received
approval from the Institutional Animal Care and Use Committee. The conditions and
duration ofthis approval are specified in the Policies ofWestern Michigan University.
You may now begin to implement the research as described in the application,

The Board wishes you success in the pursuit ofyour research goals.

Approval Termination:

March 30,201
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TERMS

IR

Insulin Receptor

IRS

Insulin Receptor Substrate

PI3K

Phosphatidylinositol-3-Kinase

Akt/PKB

Protein Kinase

mTOR

Mechanistic Target of Rapamycin

GSK3

Glycogen Synthase Kinase

GS

Glycogen Synthase

PIP2

Phosphatidylinositol 4,5-bisphosphate

PIP3

Phosphatidylinositol 3,4,5-trisphosphate

HBP

Hexosamine Biosynthesis Pathway

GFAT

B

Glutamine Fructose-6-Phosphate
Amindotransferase

IDDM

Insulin Dependent Diabetes Mellitus

NIDDM

Non-Insulin Dependent Diabetes Mellitus

BMOV

Bis(maltolato)

NaMV

Sodium Metavanadate

Na3V04

Sodium Orthovanadate

LY294002

Lilly Inhibitor 2-(4-Morpholinyl)-8-phenyl-

oxovanadium

4H-l-benzopyran-4-one
GlcNac

N-Acetyl Glucosamine
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